References: Lamotrigine for psychiatric disorders during pregnancy
Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014;(10):CD010236. https://www.ncbi.nlm.nih.gov/pubmed/25354543
Cohen-Israel M, Berger I, Martonovich EY, Klinger G, Stahl B, Linder N. Short- and long-term complications of in utero exposure to lamotrigine. Br J Clin Pharmacol 2018;84(1):189–94. https://www.ncbi.nlm.nih.gov/pubmed/29044597
Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: A systematic review. Aust N Z J Psychiatry 2017;51(11):1087–97. https://www.ncbi.nlm.nih.gov/pubmed/28825316
National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance [cg192]. London: NICE; 2014 (updated 2020). https://www.nice.org.uk/guidance/cg192
Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: A systematic review. PLoS Med 2016;13(11):e1002160. https://www.ncbi.nlm.nih.gov/pubmed/27802281
Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs 2017;31(6):439–50. https://www.ncbi.nlm.nih.gov/pubmed/28434134
Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016;11:CD010224. https://www.ncbi.nlm.nih.gov/pubmed/27819746
